Trial Profile
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Eftilagimod alpha (Primary) ; Paclitaxel (Primary) ; Dexamethasone
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors EOC Pharma
- 30 Mar 2022 Status changed from active, no longer recruiting to completed.
- 08 Apr 2020 According to an EOC Pharma media release, comapny confirmed it will continue to advance its ongoing phase I EOC202A1101 study in metastatic breast cancer in China.
- 19 Mar 2020 Results published in the Media Release